ArticleSurgical endoscopy2026
Weight matters: long-term evaluation of weight regain and fistula recurrence post endoscopic ultrasound-directed transgastric ERCP (EDGE).
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic ultrasound-directed transgastric ERCP (EDGE) is increasingly used for pancreaticobiliary access in patients with Roux-en-Y gastric bypass (RYGB). However, concerns persist regarding long-term fistula persistence and weight regain after lumen-apposing metal stent (LAMS) removal. Long-term outcome data remain limited.
methodsWe performed a retrospective study of a prospectively maintained database at a tertiary academic center including RYGB patients who underwent EDGE between June 2018 and November 2024. Outcomes included fistula persistence or recurrence after LAMS removal, weight change during LAMS indwell and long-term follow-up, technical success, and adverse events. Fistula status was assessed by imaging and/or endoscopy when available. Adverse events were graded using the AGREE classification, a validated adverse events grading system.
resultsSeventy-three patients underwent EDGE. ERCP technical success was achieved in 93%. Median LAMS indwell duration was 65 days. Objective fistula reassessment was performed in 92% of patients. Persistent or recurrent fistula was identified in 3 patients (4%), all initially treated with 20 mm LAMS and endoscopic closure, with successful repeat endoscopic therapy when pursued. Five adverse events occurred (6.8%), including four requiring surgery. During LAMS indwell, median weight change was - 1.5 kg (IQR - 4.0 to + 1.0). At median follow-up of 4.9 years after LAMS removal, median weight change was + 3.1 kg (IQR 2.4-3.3), with no statistically significant difference by fistula closure strategy or access route.
conclusionsEDGE provides effective pancreaticobiliary access in RYGB patients with low rates of long-term fistula persistence and modest weight change consistent with expected post-bariatric trajectories. These findings support the long-term safety and durability of EDGE with selective fistula closure strategies.
Indexed as
Identifiers
42414776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.